Wall Street brokerages predict that Menlo Therapeutics Inc (NASDAQ:MNLO) will announce earnings per share of ($0.81) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Menlo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($0.85). Menlo Therapeutics reported earnings per share of ($0.72) during the same quarter last year, which suggests a negative year over year growth rate of 12.5%. The firm is scheduled to issue its next earnings report on Wednesday, May 8th.
On average, analysts expect that Menlo Therapeutics will report full year earnings of ($3.39) per share for the current year, with EPS estimates ranging from ($3.57) to ($3.18). For the next financial year, analysts forecast that the business will report earnings of ($2.48) per share, with EPS estimates ranging from ($2.88) to ($1.94). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Menlo Therapeutics.
Menlo Therapeutics (NASDAQ:MNLO) last released its quarterly earnings data on Wednesday, February 27th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. Menlo Therapeutics had a negative return on equity of 34.23% and a negative net margin of 268.61%. During the same period last year, the firm earned ($1.80) EPS.
Several analysts recently weighed in on the company. Zacks Investment Research lowered Menlo Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 14th. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 price target on shares of Menlo Therapeutics in a research note on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.80.
Several hedge funds have recently made changes to their positions in MNLO. Rhumbline Advisers acquired a new stake in shares of Menlo Therapeutics during the fourth quarter valued at about $48,000. Virtu Financial LLC acquired a new stake in shares of Menlo Therapeutics during the third quarter valued at about $126,000. Acadian Asset Management LLC acquired a new stake in shares of Menlo Therapeutics during the fourth quarter valued at about $147,000. Trexquant Investment LP acquired a new stake in shares of Menlo Therapeutics during the third quarter valued at about $151,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Menlo Therapeutics by 51.0% during the fourth quarter. Bank of New York Mellon Corp now owns 38,662 shares of the company’s stock valued at $159,000 after purchasing an additional 13,064 shares in the last quarter. 71.42% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:MNLO traded up $0.27 during trading hours on Friday, hitting $7.81. The company’s stock had a trading volume of 243,170 shares, compared to its average volume of 83,958. The firm has a market capitalization of $170.25 million, a PE ratio of -3.30 and a beta of 3.70. Menlo Therapeutics has a twelve month low of $3.74 and a twelve month high of $38.82.
About Menlo Therapeutics
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.
Featured Article: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Menlo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.